Borealis Biosciences gets $150 million Series A financing from Versant Ventures and Novartis AG
VANCOUVER: Borealis Biosciences, a next-generation RNA medicines company, today emerged from stealth with $150 million in combined Series A financing from founding investor Versant Ventures and Novartis AG, as well as committed strategic research collaboration funding from Novartis. Despite recent advances…